Investigating the Therapeutic Effect of Intradermal Acupuncture for Acute Herpes Zoster and Assessing the Feasibility of Infrared Thermography for Early Prediction of Postherpetic Neuralgia: Study Protocol for a Randomized, Sham-Controlled, Clinical Trial
Hantong Hu,Yingying Cheng,Lei Wu,Dexiong Han,Ruijie Ma
DOI: https://doi.org/10.2147/JPR.S406841
IF: 2.8319
2023-04-27
Journal of Pain Research
Abstract:Hantong Hu, 1, 2, &ast Yingying Cheng, 1, &ast Lei Wu, 1 Dexiong Han, 1, 2 Ruijie Ma 1, 2 1 Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou City, People's Republic of China; 2 Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou City, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ruijie Ma; Dexiong Han, Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University, No. 548 Binwen Road, Hangzhou City, People's Republic of China, Email ; Introduction: Herpes zoster (HZ) can adversely influence patients' quality of life and sometimes it can develop postherpetic neuralgia (PHN). To date, it remains challenging to be managed by currently available therapies. Intradermal acupuncture (IDA) has the potential to be an adjunctive therapy for acute HZ and infrared thermography (IRT) may be useful for predicting PHN; however, current evidence remains inconclusive. Therefore, the purposes of this trial are to 1) evaluate the efficacy and safety of IDA as an adjunctive therapy for acute HZ; 2) to explore the feasibility of IRT for early prediction of PHN and as an objective tool to aid in subjective pain assessment in acute HZ. Methods: This study is designed as a randomized, parallel-group, sham-controlled, and patient-assessor-blinded trial, including 1-month treatment and 3-month follow-ups. Seventy-two qualified participants will be randomly split into the IDA or sham IDA group in a ratio of 1:1. Apart from standard pharmacological treatments in both groups, the two groups will receive 10 sessions of IDA or sham IDA, respectively. Primary outcome measures are the visual analog scale (VAS), indicators of herpes lesions' recovery, the temperature of the pain area, and the incidence rate of PHN. The secondary outcome is the 36-item Short Form Health Survey (SF-36). Indicators of herpes lesions' recovery will be assessed at each visit and follow-ups. The remaining outcomes will be assessed at baseline, 1 month after intervention, and 3-month follow-up. Safety evaluation will be determined by adverse events during the trial. Conclusion: Expected results will determine whether IDA can enhance therapeutic effectiveness of pharmacotherapy for acute HZ with acceptable safety profile. In addition, it will verify the accuracy of IRT for early prediction of PHN and as an objective tool of subjective pain for acute HZ. Trial Registration: Clinicaltrials.gov (identification number: NCT05348382; Registered 27 April 2022, https://clinicaltrials.gov/ct2/show/NCT05348382 ). Keywords: acupuncture, herpes zoster, postherpetic neuralgia, infrared thermography, clinical trial Herpes zoster (HZ) is featured by a band-like rash in the dermatome that corresponds to the affected nerve. Epidemiological data has revealed that it occurs annually in at least 1 million individuals in the US, 1 and the incidence rate has been increasing across the world in the past two decades. 2 It is reported that at least 20–30% of the population and up to 50% of those living until age 85 years suffer from HZ. 3,4 Patients with HZ frequently experience pain, which can be triggered by gentle touch. Other possible symptoms include a general feeling of being unwell, photophobia, headache, and malaise. Postherpetic neuralgia (PHN) is the most common sequelae of HZ, which is generally defined as persistent pain for more than 3 months after the onset of HZ rash 5 and it is generally intractable to treat. It is reported that the frequency of PHN among patients more than 60 years old was approximately 13% at 3 months and 7% at 1 year. 3 Currently, analgesic, antiviral, anti-inflammatory, and neuroleptic drugs are often used to treat HZ. 2 And vaccination strategies for HZ remain inconsistent. 6 Notably, the application of these therapies can be limited. For instance, some tricyclic antidepressants (eg, amitriptyline) can bring serious adverse events in older adults. 7 Additionally, some HZ patients fail to respond to the aforementioned drugs. Moreover, despite timely use of the aforementioned therapies, quite a few HZ patients can still develop PHN. It is worth noting that a Cochrane review concludes that acyclovir does not significantly reduce the incidence of PHN and evidence on other antiviral treatments remains insufficient. 8 Faced with such a dilemma, clinicians differ in their approaches to the -Abstract Truncated-
clinical neurology